Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Sponsors Educational Website for Nontuberculous Mycobacterium (NTM)
May 04, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, has sponsored the website to educate the public about Nontuberculous Mycobacterium (NTM).

“It is important to educate the public about the importance of NTMs, as they are a leading cause of death in HIV/AIDS and immuno-suppressed patients,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “There are currently over 40 million people suffering from HIV/AIDS that could benefit from this information. For example, most people don’t realize that NTMs can be traced to everyday events such as sitting in hot tubs at the community gym.”

The website will feature information about Nontuberculous Mycobacterium: its symptoms, diagnosis and treatments, as well as an interactive communications forum for patients and medical professionals.

“When patients go undiagnosed with Nontuberculous Mycobacterium, effects can be devastating,” commented Neil Roth, President of Designer Diagnostics. “Treatment may require multiple drugs that are known to cause severe side effects. Our ultimate goal is to prevent late stages of the NTM infections from occurring. We believe this can be accomplished by educating the patients about early detection, recognizing the symptoms and showing ways to prevent the infections from spreading.”

In March, Designer Diagnostics announced the launch of a medical diagnostics test kit for the rapid isolation and identification of Nontuberculous Mycobacterium. The TestKits were designed utilizing patents that were both licensed and acquired from NanoLogix.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Nutra Pharma sponsorship of the educational website about Nontuberculous Mycobacterium should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics